Voltage-dependent L-type calcium channel Cav1 family (Cav1)

The Voltage-dependent L-type calcium channel Cav1 family consists of four high-voltage-activated channels (Cav1.1, Cav1.2, Cav1.3, and Cav1.4) that mediate long-lasting (L-type) calcium currents in response to membrane depolarization [1, 4]. These channels are essential for coupling electrical signals to physiological responses, including excitation-contraction coupling in skeletal and cardiac muscle, hormone secretion in endocrine cells, and neurotransmitter release in the central nervous system and sensory organs [1, 6]. Cav1.1 is primarily found in skeletal muscle, while Cav1.2 and Cav1.3 are widely expressed in the heart, smooth muscle, and brain, and Cav1.4 is localized to the retina [2, 5]. Mutations in these channels are linked to various channelopathies, such as hypokalemic periodic paralysis, Timothy syndrome, and congenital stationary night blindness [2, 8]. Clinically, the Cav1 family is a major therapeutic target for cardiovascular conditions, with drugs like dihydropyridines, phenylalkylamines, and benzothiazepines acting as blockers to treat hypertension, angina, and arrhythmias [5, 16]. Emerging research also explores their role in neuroprotection for Parkinson's disease and neuropsychiatric disorders [9, 12].

Other names

L-type calcium channelsLTCCsDihydropyridine receptorsDHPRsDihydropyridine-sensitive calcium channels

Drugs targeting the Cav1 family primarily act as pore blockers or allosteric modulators that bind to the alpha-1 subunit, often showing a preference for the inactivated state of the channel [1, 15]. By inhibiting the inward flow of calcium ions during membrane depolarization, these agents reduce intracellular calcium concentrations, which leads to smooth muscle relaxation (vasodilation), decreased myocardial contractility (negative inotropy), and slowed electrical conduction in the heart [5, 7, 16].